Andreas Rummelt

Cypralis Ltd. provides novel medicines for degenerative diseases. The firm focuses on discovery of novel therapeutics based on modulation of peptidyl-prolyl isomerases. The company was founded in 2013 and is headquartered in Ongar, the United Kingdom.

LeukoCare AG develops protein stabilization and protection solutions. The firm specializes in the development of protein stabilization and protection solutions for biopharmaceuticals, vaccines, medical devices, and diagnostics technologies. Its service areas encompass technology licensing, prototyping and product development, clinical registration, biological and chemical testing, and consulting. The company was founded by Martin Scholz in 2001 and is headquartered in Munich, Germany.

Part of Celtic Holdings SCA, Alvogen Emerging Markets Holdings Ltd. is a Chinese pharmaceutical company that offers high-quality, affordable generic medications to reduce healthcare costs globally. The private company is based in Wanchai, Hong Kong. The company's growth strategy is fueled by a unique portfolio of high-quality and difficult-to-make pharmaceutical products. Alvogen's sister company, Alvotech, specializes in the development and manufacturing of high-quality biosimilar medicines. The company was founded in 2009 by Vilhelm Róbert Wessman, who has been the CEO since 2009.

Sandoz Pharmaceuticals AG develops and produces biopharmaceuticals. The firm specializes in the production of biopharmaceutical and biosimilars for the treatment and prevention of chronic diseases. It focuses on finding cure for diseases, such as cancer, multiple sclerosis, rheumatoid arthritis, and inherited metabolic disorders. The company was founded on January 6, 2006 and is headquartered in Rotkreuz, Switzerland.

Part of Celtic Holdings SCA, Alvogen Emerging Markets Holdings Ltd. is a Chinese pharmaceutical company that offers high-quality, affordable generic medications to reduce healthcare costs globally. The private company is based in Wanchai, Hong Kong. The company's growth strategy is fueled by a unique portfolio of high-quality and difficult-to-make pharmaceutical products. Alvogen's sister company, Alvotech, specializes in the development and manufacturing of high-quality biosimilar medicines. The company was founded in 2009 by Vilhelm Róbert Wessman, who has been the CEO since 2009.

LeukoCare AG develops protein stabilization and protection solutions. The firm specializes in the development of protein stabilization and protection solutions for biopharmaceuticals, vaccines, medical devices, and diagnostics technologies. Its service areas encompass technology licensing, prototyping and product development, clinical registration, biological and chemical testing, and consulting. The company was founded by Martin Scholz in 2001 and is headquartered in Munich, Germany.

LeukoCare AG develops protein stabilization and protection solutions. The firm specializes in the development of protein stabilization and protection solutions for biopharmaceuticals, vaccines, medical devices, and diagnostics technologies. Its service areas encompass technology licensing, prototyping and product development, clinical registration, biological and chemical testing, and consulting. The company was founded by Martin Scholz in 2001 and is headquartered in Munich, Germany.

LeukoCare AG develops protein stabilization and protection solutions. The firm specializes in the development of protein stabilization and protection solutions for biopharmaceuticals, vaccines, medical devices, and diagnostics technologies. Its service areas encompass technology licensing, prototyping and product development, clinical registration, biological and chemical testing, and consulting. The company was founded by Martin Scholz in 2001 and is headquartered in Munich, Germany.

Part of Celtic Holdings SCA, Alvogen Emerging Markets Holdings Ltd. is a Chinese pharmaceutical company that offers high-quality, affordable generic medications to reduce healthcare costs globally. The private company is based in Wanchai, Hong Kong. The company's growth strategy is fueled by a unique portfolio of high-quality and difficult-to-make pharmaceutical products. Alvogen's sister company, Alvotech, specializes in the development and manufacturing of high-quality biosimilar medicines. The company was founded in 2009 by Vilhelm Róbert Wessman, who has been the CEO since 2009.

Part of Celtic Holdings SCA, Alvogen Emerging Markets Holdings Ltd. is a Chinese pharmaceutical company that offers high-quality, affordable generic medications to reduce healthcare costs globally. The private company is based in Wanchai, Hong Kong. The company's growth strategy is fueled by a unique portfolio of high-quality and difficult-to-make pharmaceutical products. Alvogen's sister company, Alvotech, specializes in the development and manufacturing of high-quality biosimilar medicines. The company was founded in 2009 by Vilhelm Róbert Wessman, who has been the CEO since 2009.

LeukoCare AG develops protein stabilization and protection solutions. The firm specializes in the development of protein stabilization and protection solutions for biopharmaceuticals, vaccines, medical devices, and diagnostics technologies. Its service areas encompass technology licensing, prototyping and product development, clinical registration, biological and chemical testing, and consulting. The company was founded by Martin Scholz in 2001 and is headquartered in Munich, Germany.

LeukoCare AG develops protein stabilization and protection solutions. The firm specializes in the development of protein stabilization and protection solutions for biopharmaceuticals, vaccines, medical devices, and diagnostics technologies. Its service areas encompass technology licensing, prototyping and product development, clinical registration, biological and chemical testing, and consulting. The company was founded by Martin Scholz in 2001 and is headquartered in Munich, Germany.

Cypralis Ltd. provides novel medicines for degenerative diseases. The firm focuses on discovery of novel therapeutics based on modulation of peptidyl-prolyl isomerases. The company was founded in 2013 and is headquartered in Ongar, the United Kingdom.